No Data
No Data
A Post-Mortem on Cassava Sciences
Unpacking the Latest Options Trading Trends in Cassava Sciences
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
What's Left in Cassava After Phase 3 Setback for Alzheimer's Drug
Express News | Cassava Sciences Shares Fall 4% After 84% Slump in Previous Session
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
HolyPotatoe : The company will most likely close shop. This is such a scam management. Keeping all the feedback secret and giving out fake information that the drug has potential, and bcos they were force to abandon the test, all the worms is out of the can. This is liken to scam